Actio Biosciences begins trial of ABS-1230 for epilepsy

Actio Biosciences has begun the KYRON Phase Ib/II trial of ABS-1230, a selective oral KCNT1 inhibitor, for KCNT1-related epilepsy. The ongoing KYRON Phase Ib/II study will examine the tolerability, pharmacokinetics, and safety of ABS-1230. KCNT1-related epilepsy presents with frequent, treatment-resistant seizures. Credit: mi_viri / Shutterstock.com. Actio Biosciences has begun the KYRON Phase Ib/II trial of ABS-1230 for potassium sodium-activated channel subfamily T member 1 (KCNT1)-related epilepsy. The company is advancing ABS-1230, a selective oral KCNT1 inhibitor, to address the genetic mechanism in this severe, rare, often fatal paediatric developmental epileptic encephalopathy. LOA and PTSR Model ABBV-706 in Glioblastoma Multiforme…

Source: Clinical Trials Arena